Tissue-based methylation testing as a predictor of clinical regression in patients with high- grade cervical intraepithelial neoplasia (CIN2/3)
This post hoc analysis of the CONCERVE study demonstrates that a negative FAM19A4/miR124-2 methylation test on baseline p16INK4a block-positive CIN2/3 biopsies is a significant predictor of clinical regression, particularly in HPV16-positive women, whereas p16INK4a/Ki-67 immunoscore and HPV E4 expression showed no such association.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The cervix, the lower part of the uterus, is guarded by a cellular landscape that can sometimes change in ways that lead to cancer. These changes, known as cervical intraepithelial neoplasia, are often caused by a persistent infection with a virus called human papillomavirus. While medical guidelines recommend removing these abnormal cells to prevent cancer, the body's immune system is surprisingly capable of clearing them on its own. In fact, a significant portion of these lesions, particularly in younger women, will disappear without any surgical intervention. This creates a difficult dilemma for doctors: treat every patient to be safe, risking unnecessary surgery and potential complications for future pregnancies, or wait and see, risking the rare chance that a lesion will worsen. The challenge lies in distinguishing which women have lesions that will vanish and which have those that will persist or grow.
To solve this, researchers have begun looking for molecular clues hidden within the cells themselves. One such clue is a chemical process called DNA methylation, which acts like a switch that can turn genes on or off. In the context of cervical health, specific genes that normally help suppress tumors can have their switches flipped in a way that signals a high risk of cancer. A test that looks for these specific switches, known as the FAM19A4/miR124-2 methylation test, has shown promise in predicting whether a lesion is likely to regress. However, most of this testing has been done on swabs taken from the surface of the cervix. A new study sought to see if this same test could be performed directly on the tissue samples that pathologists already examine under a microscope, providing a more direct look at the lesion's true nature.
A team of researchers, led by Flavia Runello at Amsterdam UMC, conducted a detailed follow-up analysis of a group of women who were already part of a larger study called CONCERVE. These women had been diagnosed with high-grade cervical lesions but were small enough to be monitored closely rather than immediately removed. Over a period of two years, the researchers watched to see which lesions disappeared and which remained. The team then took the original tissue samples from these women and subjected them to a battery of tests. They looked for the presence of the specific DNA methylation markers mentioned above. They also examined the tissue for two other well-known biological signs: the amount of a protein called p16INK4a and another called Ki-67, which are often used to grade how severe a lesion is, and a protein called HPV E4, which indicates whether the virus is actively producing new copies of itself.
The results offered a clear distinction between the different types of tests. When the researchers looked at the p16INK4a and Ki-67 proteins, they found that the intensity of these markers did not help predict whether a lesion would go away. Similarly, the presence of the HPV E4 protein, which might suggest a productive viral infection, showed no link to the outcome. The story was entirely different for the DNA methylation test. Women whose tissue samples tested negative for the FAM19A4/miR124-2 methylation markers were far more likely to see their lesions disappear on their own. Specifically, about 76 percent of the women with a negative methylation test experienced clinical regression, meaning their lesions were no longer detectable or had returned to normal. In contrast, only about 45 percent of the women with a positive methylation test saw their lesions regress.
This difference was even more striking when the researchers focused on women infected with HPV16, the most common high-risk strain of the virus. Among women with this specific strain, those with a negative methylation test had a regression rate of nearly 66 percent, while those with a positive test had a regression rate of only about 30 percent. The data suggests that the methylation test provides a powerful layer of information that goes beyond what a standard microscope examination can show. It appears that even when a lesion looks severe under a microscope, the absence of these specific chemical markers indicates that the body is likely to handle the infection successfully.
The study also confirmed that the results obtained from the tissue biopsies matched closely with results from the swabs taken from the same women, suggesting that the tissue test is just as reliable. This finding is significant because it means that doctors do not necessarily need to wait for a separate swab to get this prognostic information; they can use the tissue sample they already have from the initial diagnosis. The researchers found that the traditional markers they tested, such as the protein scores and the viral production markers, did not offer this same predictive power. While the study was limited to a specific group of women with smaller lesions who were already being monitored, the findings point toward a more personalized approach to care. By identifying the women whose lesions are most likely to disappear, doctors could potentially adopt a "wait-and-see" strategy for more patients, sparing them from surgery and its associated risks, while still keeping a close watch on those whose lesions are more likely to persist.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.